Does rational therapy exist in patients with Crohn’s disease and ulcerative colitis?

Czech version

Authors: M. Lukáš ^1,2
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty ISCARE Lighthouse a 1. lékařská fakulta UK Praha, přednosta prof. MUDr. Milan Lukáš, CSc. ¹; Ústav klinické biochemie a laboratorní diagnostiky 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Tomáš Zima, DrSc., MBA ²
Published in: Vnitř Lék 2011; 57(12): 1029-1033
Category: 70th birthday of prof. MUDr. Petr Dítě, DrSc.

Overview

Crohn’s disease and ulcerative colitis belong to an autoimmune mediated, civilizing diseases having a rise of incidence. The cause of both disease is still unknown with undoubted importance of diet, a lifestyle and using of antimicrobial drugs in the last fifty years. The rational therapy is based to use the drugs with high anti-inflammatory efficacy. The choice of therapy is driven due to disease course in individual patient. The integral part of patients follow up are activities directing to minimize of drug’s side effects.

Key words:
Crohn’s disease – ulcerative colitis – aminosalicylates – glucocorticosteroids – immunosuppresants – biologic therapy

Sources

1. Lukáš M, Bortlík M. Etiologie a patogeneze ulcerózní kolitidy. Stále více otazníků než jasných odpovědí. Gastroent a hepatol 2011; 65: 56–64.

2. Lukáš M, Ďuricová D, Bortlík M. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů. Čes a Slov Gastroent a Hepatol 2008; 62: 285–291.

3. Hoentjen F, Sakuraba A, Hanauer S. Update on the Management of Ulcerative Colitis. Curr Gastroenterol Rep 2011; 13: 475–485.

4. Manza M, Michetti P, Seibold F et al. Treatment algorithm for moderate to severe ulcerative colitis. Swiss Med Wkly 2011; 141: w13235. doi: 10.4414/smw.2011.13235.

5. Lichtiger S, Present DH, Kornbluth A et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841–1845.

6. Van Assche G, D’Haens G, Noman M et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025–1031.

7. Travis SP, Stange EF, Léman M et al. European Crohn’s and Colitis Organisation (ECCO). European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis 2008; 2: 24–62.

8. Huang X, Lv B, Jin H et al. A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis. Eur J Clin Pharmacol 2011; 67: 759–766.

9. Oussalah A, Evesque L, Laharie D et al. A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. Am J Gastroenterol 2010; 105: 2617–2625.

10. Carter CT, Leher H, Smith P. Impact of persistence with Infliximab on hospitalizations in ulcerative colitis. Am J Manag Care 2011; 17: 385–392.